glp 1 receptor agonists examples A Closer Look at the Dermatological Profile of GLP-1 Mapping the effectiveness and risks

Ozempic and Wegovy users focus on nausea and vomiting

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

Learn about this investigational triple-agonist (GLP-1/GIP/glucagon) showing 24% weight loss, how it works, FDA status, dosing, side effects, and how to access it.

With so many people interested in using GLP-1 agonists off-label to lose a few extra pounds, what does it mean for this class of drugs?